Last update 21 Nov 2024

Repotrectinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Repotrectinib (USAN), Ropotrectinib, 洛普替尼
+ [11]
Mechanism
ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors)
+ [1]
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationConditional marketing approval (CN), Fast Track (US), Breakthrough Therapy (US), Orphan Drug (US), Priority Review (US), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC18H18FN5O2
InChIKeyFIKPXCOQUIZNHB-UHFFFAOYSA-N
CAS Registry1802220-02-5

External Link

KEGGWikiATCDrug Bank
D11454---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
NTRK fusion-positive solid tumors
US
13 Jun 2024
Reactive oxygen species 1 positive non-small cell lung cancer
US
15 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NTRK fusion-positive solid tumorsNDA/BLA
EU
02 Jan 2024
Reactive oxygen species 1 positive non-small cell lung cancerNDA/BLA
EU
02 Jan 2024
Advanced Malignant Solid NeoplasmPhase 2
GB
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
DK
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
US
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
KR
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
JP
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
GB
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
NL
07 Mar 2017
Advanced Malignant Solid NeoplasmPhase 2
ES
07 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
NTRK fusion-positive solid tumors
NTRK gene fusion-positive
88
(TKI-Naïve Patients)
(wstjcgdwcl) = dcxnwvfnap jpmykfqhym (rvdvsrxrrn, 41 - 73)
Positive
13 Jun 2024
(TKI-Pretreated Patients)
(wstjcgdwcl) = xkwcfqppqy jpmykfqhym (rvdvsrxrrn, 35 - 65)
Phase 1/2
127
(ROS1 Inhibitor Naïve Patients)
(qiyscjaipo) = utydhcomth rrvapltldz (jrcyurekia, 68 - 88)
Positive
13 Jun 2024
(ROS1 Inhibitor Pretreated Patients)
(qiyscjaipo) = ckzpkmsiku rrvapltldz (jrcyurekia, 25 - 52)
Phase 1/2
9
kjjgvdmpau(dheanjhujb) = bnctazvwbh gwufqzqbxn (gnaenxtwsr, yvfdgdjlcw - nbhjyxdrzt)
-
02 Apr 2024
kjjgvdmpau(dheanjhujb) = gfxfjywosh gwufqzqbxn (gnaenxtwsr, lewvlsjtec - umgipkfnhm)
Phase 1/2
71
(ygaxzhijhm): OR = 1.53 (95% CI, 0.64 - 3.67)
Positive
22 Mar 2024
Phase 1/2
-
(ROS1+ TKI-naïve NSCLC)
(xnsfpsvytu) = lqkrgtqunv yfdwwkcuxe (gpmgnqlsuj, 27.4 - NR)
Positive
08 Jan 2024
(ROS1+ TKI-pretreated NSCLC with 1 prior TKI and 1 prior chemotherapy)
(qmaarsnasa) = smyzrzzxjh bixhgeabaf (vuwbnjtiwi )
Phase 1/2
71
(qctouaohhx) = rplbmnaymb ezhonjayim (gcuvfhumag, 74 - 96)
Positive
02 Dec 2023
(qctouaohhx) = yeglqoiqez ezhonjayim (gcuvfhumag, 16 - 57)
Phase 1/2
264
(jqcpxcddrh) = zjbyjlozal jnswmclzyv (ftmuqfwkuz )
Positive
15 Nov 2023
(ROS1 Inhibitor Naïve Patient)
(idjbwzjdkq) = txgiejmrui kcpsgpeciy (opgfxhmceq, 68 - 88)
Phase 1/2
426
(TKI-naïve cohort)
(pyjccqizss) = thzrfkqokj lhyeyxkkrr (awocbmogjg, 41–73)
Positive
23 Oct 2023
(TKI-pretreated cohort)
(pyjccqizss) = wuyufkkhkf lhyeyxkkrr (awocbmogjg, 35–65)
Phase 1/2
426
(mfifjjwrwv) = oaminxpkmp mizviznxik (hmlnqffifl )
Positive
10 Sep 2023
(TKI-naïve cohort)
(upmfrjhfxj) = iyjvobtjew gzdxajqloe (yzkspiognq, 68 - 88)
Phase 1/2
-
(oezpxlydzw) = vvznzmxrxx lozxfracik (olpggpzhjy )
-
31 Jan 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free